We report the case of a 44-year-old male patient who presented with acute renal artery occlusion, 3 d after frst injection of infiximab for steroid refractory attack of ulcerative colitis. Extensive work-up provided n...We report the case of a 44-year-old male patient who presented with acute renal artery occlusion, 3 d after frst injection of infiximab for steroid refractory attack of ulcerative colitis. Extensive work-up provided no evidence of predisposing factors for arterial thrombosis. Infiximab was thus suspected in the genesis of throm-bosis, based on both intrinsic and extrinsic criteria. At month 3 after thrombosis with ongoing anticoagulation, angio-tomodensitometry showed complete revascularization of the left renal artery with renal atrophy. Renal function remained normal and the patient was still in steroid free remission on mercaptopurin monotherapy at maximal follow-up. Few thromboembolic events have been described with anti- tumor necrosis factor （TNF） agents, but it is the frst case reported of renal artery thrombosis after infiximab infusion. In addition, we re-view thrombosis associated with anti-TNF agents.展开更多
文摘We report the case of a 44-year-old male patient who presented with acute renal artery occlusion, 3 d after frst injection of infiximab for steroid refractory attack of ulcerative colitis. Extensive work-up provided no evidence of predisposing factors for arterial thrombosis. Infiximab was thus suspected in the genesis of throm-bosis, based on both intrinsic and extrinsic criteria. At month 3 after thrombosis with ongoing anticoagulation, angio-tomodensitometry showed complete revascularization of the left renal artery with renal atrophy. Renal function remained normal and the patient was still in steroid free remission on mercaptopurin monotherapy at maximal follow-up. Few thromboembolic events have been described with anti- tumor necrosis factor （TNF） agents, but it is the frst case reported of renal artery thrombosis after infiximab infusion. In addition, we re-view thrombosis associated with anti-TNF agents.
